K 3 Tumor ‐ intrinsic beta ‐ catenin signaling mediates tumor ‐ immune avoidance

s 2014;32:8112.

[1]  S. Demaria,et al.  Role of Local Radiation Therapy in Cancer Immunotherapy. , 2015, JAMA oncology.

[2]  S. Demaria,et al.  Abscopal Responses in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated on a Phase 2 Study of Combined Radiation Therapy and Ipilimumab: Evidence for the In Situ Vaccination Hypothesis of Radiation , 2015 .

[3]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[4]  J. Zavadil,et al.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. , 2015, Cancer research.

[5]  David C. Smith,et al.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[7]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[8]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[9]  Jeffrey E. Lee,et al.  C-reactive protein as a marker of melanoma progression. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Tortora,et al.  Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? , 2015, Anti-cancer agents in medicinal chemistry.

[11]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[12]  Hui Li,et al.  Long noncoding RNA HOTAIR involvement in cancer , 2014, Tumor Biology.

[13]  F. Fulciniti,et al.  SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression , 2014, Virchows Archiv.

[14]  S. Cinca,et al.  Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma , 2014, Journal of skin cancer.

[15]  David C. Smith,et al.  Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. , 2014 .

[16]  S. Rosenberg,et al.  Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma? , 2014, Nature Reviews Clinical Oncology.

[17]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[18]  N. Soshnikova.  Hox genes regulation in vertebrates , 2014, Developmental dynamics : an official publication of the American Association of Anatomists.

[19]  A. Weaver,et al.  Cystathionine Beta-Synthase (CBS) Contributes to Advanced Ovarian Cancer Progression and Drug Resistance , 2013, PloS one.

[20]  S. Demaria,et al.  An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.

[21]  W. Travis,et al.  New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Demaria,et al.  Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.

[23]  Sacha Gnjatic,et al.  The abscopal effect associated with a systemic anti-melanoma immune response. , 2013, International journal of radiation oncology, biology, physics.

[24]  S. Swetter,et al.  A systemic complete response of metastatic melanoma to local radiation and immunotherapy. , 2012, Translational oncology.

[25]  G. Botti,et al.  Microenvironment and tumor progression of melanoma: New therapeutic prospectives , 2012, Journal of immunotoxicology.

[26]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[27]  F. Fulciniti,et al.  Increased HOX C13 expression in metastatic melanoma progression , 2012, Journal of Translational Medicine.

[28]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[29]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[30]  M. McKeage,et al.  Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. , 2010, Journal of thoracic disease.

[31]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[33]  C. Théry,et al.  Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. , 2005, Blood cells, molecules & diseases.

[34]  W. Stolz,et al.  Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. , 1997, Cancer research.

[35]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[36]  Myriam Gorospe,et al.  HuR function in disease. , 2012, Frontiers in bioscience.

[37]  W. Söllner,et al.  Need for supportive counselling--the professionals' versus the patients' perspective. A survey in a representative sample of 236 melanoma patients. , 1998, Psychotherapy and psychosomatics.